Response by Prisco and Prins to Letter Regarding Article, "Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility"

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)E009570
JournalCirculation: Heart Failure
Issue number8
StatePublished - Aug 1 2022

Bibliographical note

Funding Information:
Drs Prisco and Prins have a provisional patent for use of SC-144 in right ventricular dysfunction. Dr Prins served on an advisory board for Actelion and Edwards and receives grant funding from United Therapeutics.

Funding Information:
Dr Prisco is funded by National Institutes of Health (NIH) F32 HL154533 and a University of Minnesota Clinical and Translational Science award (NIH UL1 TR002494). Dr Prins is funded by NIH K08 HL140100 and R01s HL162927 and HL158795 and American Lung Association Innovative Award IA-816386. The content is solely the responsibility of the authors and does not represent the official views of the NIH or any other funding sources.

PubMed: MeSH publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

Cite this